S

Synklino

25 employees

Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care

Date founded

2017

Funding rounds raised

Total raised

$32M

from 7 investors over 7 rounds

S

Synklino raised $32M on June 8, 2022

Investors: Vækstfonden, Eir Ventures, LD INVEST and PKA

S

Synklino raised undisclosed on September 29, 2020

Investors: Vækstfonden and Eir Ventures

S

Synklino raised $1.5M on August 1, 2019

Investors: BioInnovation Institute

FAQ